Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 109 people in total across six groups. Each group received a small implant placed in the eye that slowly released different doses of a medicine called bimatoprost — either a first-generation or second-generation version of the implant — alongside bimatoprost eye drops (0.03%). The trial was measuring eye pressure (the fluid pressure inside the eye), which is relevant in conditions like glaucoma. The main thing the trial was tracking was how much eye pressure changed from the start of the study to later time points. The reported data shows that at the start of the study, average eye pressure across the six groups ranged from about 23.7 to 26.6 mmHg (millimetres of mercury, the unit used to measure pressure). After treatment, the reported change from that starting pressure ranged from about −5.5 to −8.8 mmHg depending on the group, meaning pressure readings were lower at follow-up than at the start. The reported follow-up pressure readings across all groups ranged from roughly 17.0 to 18.2 mmHg. When eye pressure was averaged across multiple time points during the day (called mean diurnal IOP), the reported figures at follow-up ranged from about 16.4 to 17.9 mmHg, compared to starting values of roughly 20.8 to 23.7 mmHg. The trial also recorded how many days passed before a second treatment or a rescue treatment was needed in the study eye; the reported figures ranged from about 237 days in one group up to approximately 411 days in another. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35643967) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Glaucoma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with open angle glaucoma or high pressure in your eyes (ocular hypertension)
Who may not be able to join:
- You have other health conditions that are not well managed or under control
- You plan to wear contact lenses at any point during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Allergan
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Time-Matched Intraocular Pressure (IOP) in the Study Eye
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.